more

QIAGEN (QGEN)

(Real Time Quote from BATS)

$42.90 USD

+0.21 (0.49%)

Updated Oct 18, 2024 02:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QIAGEN Launches Assay for Cancer Patients Following FDA's Nod

by Zacks Equity Research Published on April 17,2020

QIAGEN (QGEN) paves the way for metastatic CRC treatment in adults with the launch of an FDA-approved companion diagnostic test kit.

QIAGEN (QGEN) Reports Preliminary Revenue Results for Q1

by Zacks Equity Research Published on April 15,2020

Investors remain optimistic with QIAGEN's (QGEN) first-quarter 2020 preliminary revenue results, which is likely to benefit from increased testing demand for coronavirus infection.

medical

ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research Published on April 10,2020

ALXN vs. QGEN: Which Stock Is the Better Value Option?

These Medical ETFs & Stocks Deserve a Salute on Health Day

by Sanghamitra Saha Published on April 07,2020

The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

etfs
medical

Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress

by Sweta Jaiswal, FRM Published on April 06,2020

It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.

etfs
medical

Can Economic Stimulus Save MedTech From Coronavirus Doldrums?

by Trina Mukherjee Published on April 02,2020

Following the announcement of the agreement to pass the historic stimulus bill, we look into four MedTech stocks that stand to gain from the same.

medical

Varian Unveils Proton Treatment Planning Eclipse v16 System

by Zacks Equity Research Published on April 01,2020

The launch of this system is a step forward in Varian's (VAR) commitment toward strengthening its Proton Solutions segment.

medical

Abbott (ABT) Rides on Point-of-Care Coronavirus Test Launch

by Zacks Equity Research Published on March 31,2020

Abbott (ABT) launches a portable molecular point-of-care test to speed up coronavirus detection, especially in areas with severe outbreaks.

medical

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

by Zacks Equity Research Published on March 31,2020

Investors continue to be optimistic about Abbott (ABT) on its strong segmental results in the fourth quarter of 2019.

medical

Medtronic's Evolut TAVR System Shows Positive Study Results

by Zacks Equity Research Published on March 30,2020

Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.

medical

4 MedTech Stocks Set to Rebound Post Coronavirus-Led Crisis

by Zacks Equity Research Published on March 30,2020

Here are some MedTech stocks which are steadily inching toward a trend reversal after registering record declines over the past few weeks.

medical

4 Stocks Countering Coronavirus Battle With Testing Kits

by Urmimala Biswas Published on March 30,2020

While the market bloodbath is showing no signs of dissipating any time soon, investors might keep an eye on certain genetic testing and medical device companies.